Company
Cannasouth Ltd
Headquarters: Hamilton, New Zealand
CEO: Mr. Mark John Lucas
Market Cap
NZ$40.7 Million
NZD as of Jan. 1, 2024
US$25.7 Million
Top Competitors by Market Capitalization
Industry: Drug Manufacturers—Specialty & Generic
| Company | Market Cap (USD) |
|---|---|
| Zoetis Inc. | $89.09 B |
| MERCK Kommanditgesellschaft auf Aktien | $67.64 B |
| Takeda Pharmaceutical Company Limited | $47.71 B |
| Haleon plc | $38.90 B |
| PPD, Inc. | $16.58 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Detailed Description
Cannasouth Limited, a biopharmaceutical company, engages in the research, development, production, and supply of cannabis biomass and cannabinoid medicines in New Zealand. The company was incorporated in 2018 and is based in Hamilton, New Zealand.
Top 1-year algo backtest: +269.94%
$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Stocks & Indices
Cannasouth Ltd has the following listings and related stock indices.
Stock: NZX: CBD wb_incandescent